: The European Society for Radiotherapy and Oncology (ESTRO) has advocated the establishment of guidelines to optimise precision radiotherapy (RT) in conjunction with contemporary therapeutics for cancer care. Quality assurance in RT (QART) plays a pivotal role in influencing treatment outcomes. Clinical trials incorporating QART protocols have demonstrated improved survival rates with minimal associated toxicity. Nonetheless, in routine clinical practice, there can be variability in the indications for RT, dosage, fractionation, and treatment planning, leading to uncertainty. In pivotal trials reporting outcomes of systemic therapy for breast cancer, there is limited information available regarding RT, and the potential interaction between modern systemic therapy and RT remains largely uncharted. This article is grounded in a consensus recommendation endorsed by ESTRO, formulated by international breast cancer experts. The consensus was reached through a modified Delphi process and was presented at an international meeting convened in Florence, Italy, in June 2023. These recommendations are regarded as both optimal and essential standards, with the latter aiming to define the minimum requirements. A template for a case report form (CRF) has been devised, which can be utilised by all clinical breast cancer trials involving RT. Optimal requirements include adherence to predefined RT planning protocols and centralised QART. Essential requirements aim to reduce variations and deviations from the guidelines in RT, even when RT is not the primary focus of the trial. These recommendations underscore the significance of implementing these practices in both clinical trials and daily clinical routines to generate high-quality data.

Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO) / Kaidar-Person, Orit; Meattini, Icro; Boersma, Liesbeth J; Becherini, Carlotta; Cortes, Javier; Curigliano, Giuseppe; de Azambuja, Evandro; Harbeck, Nadia; Rugo, Hope S; Del Mastro, Lucia; Gennari, Alessandra; Isacke, Clare M; Vestmø Maraldo, Maja; Marangoni, Elisabetta; Nader Marta, Gustavo; Mjaaland, Ingvil; Salvestrini, Viola; Spanic, Tanja; Visani, Luca; Morandi, Andrea; Lambertini, Matteo; Livi, Lorenzo; Coles, Charlotte E; Poortmans, Philip; Offersen, Birgitte V. - In: RADIOTHERAPY AND ONCOLOGY. - ISSN 0167-8140. - ELETTRONICO. - (2023), pp. 0-0. [10.1016/j.radonc.2023.110060]

Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

Meattini, Icro;Becherini, Carlotta;Salvestrini, Viola;Visani, Luca;Morandi, Andrea;Livi, Lorenzo;
2023

Abstract

: The European Society for Radiotherapy and Oncology (ESTRO) has advocated the establishment of guidelines to optimise precision radiotherapy (RT) in conjunction with contemporary therapeutics for cancer care. Quality assurance in RT (QART) plays a pivotal role in influencing treatment outcomes. Clinical trials incorporating QART protocols have demonstrated improved survival rates with minimal associated toxicity. Nonetheless, in routine clinical practice, there can be variability in the indications for RT, dosage, fractionation, and treatment planning, leading to uncertainty. In pivotal trials reporting outcomes of systemic therapy for breast cancer, there is limited information available regarding RT, and the potential interaction between modern systemic therapy and RT remains largely uncharted. This article is grounded in a consensus recommendation endorsed by ESTRO, formulated by international breast cancer experts. The consensus was reached through a modified Delphi process and was presented at an international meeting convened in Florence, Italy, in June 2023. These recommendations are regarded as both optimal and essential standards, with the latter aiming to define the minimum requirements. A template for a case report form (CRF) has been devised, which can be utilised by all clinical breast cancer trials involving RT. Optimal requirements include adherence to predefined RT planning protocols and centralised QART. Essential requirements aim to reduce variations and deviations from the guidelines in RT, even when RT is not the primary focus of the trial. These recommendations underscore the significance of implementing these practices in both clinical trials and daily clinical routines to generate high-quality data.
2023
0
0
Kaidar-Person, Orit; Meattini, Icro; Boersma, Liesbeth J; Becherini, Carlotta; Cortes, Javier; Curigliano, Giuseppe; de Azambuja, Evandro; Harbeck, Nadia; Rugo, Hope S; Del Mastro, Lucia; Gennari, Alessandra; Isacke, Clare M; Vestmø Maraldo, Maja; Marangoni, Elisabetta; Nader Marta, Gustavo; Mjaaland, Ingvil; Salvestrini, Viola; Spanic, Tanja; Visani, Luca; Morandi, Andrea; Lambertini, Matteo; Livi, Lorenzo; Coles, Charlotte E; Poortmans, Philip; Offersen, Birgitte V
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0167814023093672-main.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 567.1 kB
Formato Adobe PDF
567.1 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1353993
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact